21世纪高密度脂蛋白:未来HDL研究的多功能路线图
该综述指出低HDL-C与心血管风险相关,但孟德尔随机化分析未发现HDL-C水平与心血管风险的因果关系,提升HDL-C的疗法均未成功。HDL由不同亚群组成,具有逆向胆固醇转运、抗炎抗氧化和抗糖尿病等多重功能,且可呈抗炎或促炎表型。HDL功能标志物(如胆固醇流出能力)与冠心病相关但仍属研究工具,未来治疗策略应聚焦在合适患者和疾病阶段优化HDL功能。
要点
- 低HDL-C与心血管风险相关,但孟德尔随机化未发现因果关系,单纯升高HDL-C并非有效治疗靶点。
- HDL功能包括逆向胆固醇转运、抗炎抗氧化和抗糖尿病,且可呈抗炎或促炎双重表型。
- HDL功能标志物胆固醇流出能力与冠心病相关,但尚属研究工具,未来应优化HDL功能。
核心结论
- HDL-C水平与心血管风险相关但无因果证据,提升HDL-C的疗法均未成功,未来应聚焦优化HDL功能而非单纯升高HDL-C。
研究设计与样本
- 综述类文章,检索范围及样本量未在原文报告。
主要发现
- 低HDL-C与心血管风险、炎症性疾病、恶性肿瘤、糖尿病等风险增加相关。
- 孟德尔随机化分析未发现HDL-C水平与心血管风险之间存在因果关系的证据。
- HDL由大小、电荷和组成不同的亚群组成,具有逆向胆固醇转运、抑制炎症和氧化、抗糖尿病等动态且依赖环境的功能。
- HDL可呈抗炎(可能抗动脉粥样硬化和糖尿病)和促炎(可能有助于脓毒症清除病原体)两种表型。
- HDL生物标志物(HDL-C、HDL颗粒数、载脂蛋白A-I)与心血管结局呈非线性关系,且因性别和种族而异,冠状动脉与非冠状动脉事件模式不同。
关键数值与推荐
- 低HDL-C定义、具体阈值及推荐条款原文未报告。
临床怎么用
- 不应将单纯升高HDL-C作为治疗目标,应关注HDL功能评估。
- HDL功能标志物(如胆固醇流出能力)目前仅用于研究,尚未进入临床常规。
- 未来治疗策略应聚焦在合适患者和疾病阶段优化HDL功能。
局限性
- 原文未报告综述的检索范围、纳入标准及样本量等设计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low high-density lipoprotein cholesterol (HDL-C) characterizes an atherogenic dyslipidemia that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular risk. Low HDL-C is also associated with increased risk of inflammatory disorders, malignancy, diabetes, and other diseases. This epidemiologic evidence has not translated to raising HDL-C as a viable therapeutic target, partly because HDL-C does not reflect high-density lipoprotein (HDL) function. Mendelian randomization analyses that have found no evidence of a causal relationship between HDL-C levels and cardiovascular risk have decreased interest in increasing HDL-C levels as a therapeutic target. HDLs comprise distinct subpopulations of particles of varying size, charge, and composition that have several dynamic and context-dependent functions, especially with respect to acute and chronic inflammatory states. These functions include reverse cholesterol transport, inhibition of inflammation and oxidation, and antidiabetic properties. HDLs can be anti-inflammatory (which may protect against atherosclerosis and diabetes) and proinflammatory (which may help clear pathogens in sepsis). The molecular regulation of HDLs is complex, as evidenced by their association with multiple proteins, as well as bioactive lipids and noncoding RNAs. Clinical investigations of HDL biomarkers (HDL-C, HDL particle number, and apolipoprotein A through I) have revealed nonlinear relationships with cardiovascular outcomes, differential relationships by sex and ethnicity, and differential patterns with coronary versus noncoronary events. Novel HDL markers may also have relevance for heart failure, cancer, and diabetes. HDL function markers (namely, cholesterol efflux capacity) are associated with coronary disease, but they remain research tools. Therapeutics that manipulate aspects of HDL metabolism remain the holy grail. None has proven to be successful, but most have targeted HDL-C, not metrics of HDL function. Future therapeutic strategies should focus on optimizing HDL function in the right patients at the optimal time in their disease course. We provide a framework to help the research and clinical communities, as well as funding agencies and stakeholders, obtain insights into current thinking on these topics, and what we predict will be an exciting future for research and development on HDLs.
引用
- Rohatgi A, Westerterp M, von Eckardstein A, et al. HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Circulation. 2021. PMID: 34097448. doi:10.1161/CIRCULATIONAHA.120.044221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。